Neoadjuvant chemotherapy alone or combined with trans-arterial therapies for downstaging unresectable intrahepatic cholangiocarcinoma to surgical resection: a narrative review

Abstract

Intrahepatic cholangiocarcinoma (ICCA) incidence has been rising in the last few decades. Currently, hepatic resection is the only curative treatment for ICCA, and there is a lack of evidence supporting the use of preoperative treatment. A narrative review was conducted to analyze the available literature published on the role of neoadjuvant chemotherapy (CHT), either alone or combined with intra-arterial therapies (IAT), for downstaging unresectable ICCA to surgical resection. Most of the studies included in this review showed that secondary resection was associated with improvement in overall survival. In particular, studies analyzing CHT alone reported the highest conversion rate ranging from 20% to 57.1%, confirming that systemic treatment may yield the best results, and therefore, it should always be included as part of the neoadjuvant protocol. Among all the IATs, the longest overall survival reported was after CHT plus hepatic artery infusion, 25 months. Downsizing neoadjuvant multimodal approach, including combined systemic therapy with IAT, might improve the long-term outcomes of unresectable patients and expand surgical indications. However, randomized controlled trials are necessary to confirm their effectiveness.

Keywords

Cholangiocarcinoma / chemotherapy / locoregional

References

[1] Singal AK,Grady JJ.Intra-hepatic cholangiocarcinoma-frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center.J Cancer Res Clin Oncol2011;137:1071-8

[2] Banales JM,Lamarca A.Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Nat Rev Gastroenterol Hepatol2020;17:557-88. PMCID:PMC7447603

[3] Zhang XF,Bagante F.Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent.Br J Surg2018;105:848-56.

[4] Lamarca A,Utpatel K.Group: on behalf of the European Network for the Study of Cholangiocarcinoma (ENS-CCA)Liver metastases of intrahepatic cholangiocarcinoma: implications for an updated staging system.Hepatology2021;73:2311-25 PMCID:PMC8252018

[5] Tsilimigras DI,Wu L.Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches.JAMA Surg2020;155:823-31 PMCID:PMC7344787

[6] Tian X,Li Y.The expression of S100A4 protein in human intrahepatic cholangiocarcinoma: clinicopathologic significance and prognostic value.Pathol Oncol Res2015;21:195-201

[7] Valle JW,Nervi B,Zhu AX.Biliary tract cancer.Lancet2021;397:428-44

[8] Machairas N,Jayant K,Sotiropoulos GC.Intrahepatic cholangiocarcinoma: limitations for resectability, current surgical concepts and future perspectives.Eur J Surg Oncol2020;46:740-6

[9] de Jong MC,Sotiropoulos GC.Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.J Clin Oncol2011;29:3140-5

[10] Hyder O,Sotiropoulos GC.Recurrence after operative management of intrahepatic cholangiocarcinoma.Surgery2013;153:811-8 PMCID:PMC3980567

[11] Adam R,Pascal G.Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.Ann Surg2004;240:644-57; discussion 657 PMCID:PMC1356466

[12] Turrini O,Moureau-Zabotto L.Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.Eur J Surg Oncol2009;35:1306-11

[13] Bismuth H,Lévi F.Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.Ann Surg1996;224:509-20; discussion 520 PMCID:PMC1235414

[14] Kato A,Ohtsuka M.Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study.Ann Surg Oncol2013;20:318-24

[15] Kato A,Ohtsuka M.Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery.Ann Surg Oncol2015;22 Suppl 3:S1093-9

[16] Rayar M,Edeline J.Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment.Ann Surg Oncol2015;22:3102-8

[17] Valle J,Palmer DH.ABC-02 Trial InvestigatorsCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010;362:1273-81

[18] Le Roy B,Pittau G.Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma.Br J Surg2018;105:839-47

[19] Konstantinidis IT,Do RK.Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.Cancer2016;122:758-65 PMCID:PMC4764409

[20] Cercek A.Locoregional therapy plus systemic chemotherapy in unresectable intrahepatic cholangiocarcinoma-reply.JAMA Oncol2020;6:935-6

[21] Buettner S,Margonis GA.Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis.J Vasc Interv Radiol2020;31:1035-1043.e2

[22] Bargellini I,Pizzi G.Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study.Cardiovasc Inter Rad2020;43:1305-14

[23] Helmberger T,Pech M.On behalf of the CIRT Steering CommitteeOn behalf of the CIRT Principal InvestigatorsClinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for SIR-Spheres therapy (CIRT).Cardiovasc Inter Rad2021;44:21-35 PMCID:PMC7728645

[24] Edeline J,Guiu B.Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial.JAMA Oncol2020;6:51-9 PMCID:PMC6824230

[25] Aliberti C,Sarti D.Chemoembolization with drug-eluting microspheres loaded with doxorubicin for the treatment of cholangiocarcinoma.Anticancer Res2017;37:1859-63

[26] Schiffman SC,Dubel G.Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival.Ann Surg Oncol2011;18:431-8.

[27] Beal EW,Moris D.Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma.Hepatobiliary Surg Nutr2018;7:270-6. PMCID:PMC6131266

[28] Akateh C,Pawlik TM.Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma.World J Hepatol2020;12:693-708 PMCID:PMC7643214

[29] Amini N,Spolverato G,Herman JM.Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis.J Surg Oncol2014;110:163-70

[30] Saxena A,Chua TC,Morris DL.Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.Ann Surg Oncol2010;17:484-91

[31] Serenari M,Cucchetti A.Deceased donor liver transplantation after radioembolization for hepatocellular carcinoma and portal vein tumoral thrombosis: a pilot study.Liver Transpl2021;27:1758-66 PMCID:PMC9290139

[32] Abou-Alfa GK,Hollebecque A.Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol2020;21:671-84 PMCID:PMC8461541

[33] Zhu AX,Javle MM.Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with idh1 mutation: the phase 3 randomized clinical ClarIDHy trial.JAMA Oncol2021;7:1669-77 PMCID:PMC8461552

[34] Oh DY,Lee DW.Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.Lancet Gastroenterol Hepatol2022;7:522-32

[35] Swinburne NC,Besa C.Radioembolization for unresectable intrahepatic cholangiocarcinoma: review of safety, response evaluation criteria in solid tumors 1.1 imaging response and survival.Cancer Biother Radiopharm2017;32:161-8.

[36] Shaker TM,Varma MK.Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma?.Am J Surg2018;215:467-70